Role of Acid Sphingomyelinase–Induced Signaling in Melanoma Cells for Hematogenous Tumor Metastasis

Alexander Carpinteiro\textsuperscript{ab}, Nadine Beckmann\textsuperscript{a} Aaron Seitz\textsuperscript{b} Gabriele Hessler\textsuperscript{a} Barbara Wilker\textsuperscript{a} Matthias Soddemann\textsuperscript{a} Iris Helfrich\textsuperscript{d} Bärbel Edelmann\textsuperscript{a} Erich Gulbins\textsuperscript{a,c} Katrin Anne Becker\textsuperscript{a}

\textsuperscript{a}Department of Molecular Biology, \textsuperscript{b}Clinic for Hematology and \textsuperscript{c}Clinic for Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; \textsuperscript{c}Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Key Words
Tumor metastasis • p38 kinase • Ceramide • Sphingolipids • Signaling

Abstract

\textbf{Background:} Hematogenous metastasis of malignant tumor cells is a multistep process that requires release of tumor cells from the local tumor mass, interaction of the tumor cells with platelets in the blood, and adhesion of either the activated tumor cells or the complexes of platelets and tumor cells to the endothelial cells of the target organ. We have previously shown that the interaction of melanoma cells with platelets results in the release of acid sphingomyelinase (Asm) from activated platelets. Secreted platelet-derived Asm acts on malignant tumor cells to cluster and activate integrins; such clustering and activation are necessary for tumor cell adhesion to endothelial cells and for metastasis.

\textbf{Methods:} We examined the response of tumor cells to treatment with extracellular sphingomyelinase or co-incubation with wild-type and Asm-deficient platelets. We determined the phosphorylation and activation of several intracellular signaling molecules, in particular p38 kinase (p38K), phospholipase C\textsubscript{γ} (PLC\textsubscript{γ}), ezrin, and extracellular signal-regulated kinases.

\textbf{Results:} Incubation of B16F10 melanoma cells with Asm activates p38 MAP kinase (p38K), phospholipase C\textsubscript{γ} (PLC\textsubscript{γ}), ezrin, and extracellular signal-regulated kinases. Co-incubation of B16F10 melanoma cells with wild-type or Asm-deficient platelets revealed that the phosphorylation/activation of p38K is dependent on Asm. Pharmacological blockade of p38K prevents activation of β1 integrin and adhesion in vitro. Most importantly, inhibition of p38K activity in B16F10 melanoma cells prevents tumor cell adhesion and metastasis to the lung in vivo, a finding indicating the importance of p38K for metastasis.

\textbf{Conclusions:} Asm, secreted from activated platelets after tumor cell-platelet contact, induces p38K phosphorylation in tumor cells. This in turn stimulates β1 integrin activation that is necessary for adhesion and subsequent metastasis of tumor cells. Thus, inhibition of p38K might be a novel target to prevent tumor metastasis.
Introduction

Hematogenous tumor metastasis is a hallmark of the development of malignant tumors and severely affects the prognosis of a patient with a malignant tumor. Tumor metastasis is a complex, multistep process initiated by the invasion of tumor cells into blood vessels, the interaction of these tumor cells with platelets, leukocytes, endothelial cells and components of the extracellular matrix, and finally the migration of the tumor cells to a distant parenchyma [1]. The blood is a rather hostile environment for tumor cells; many of them are rapidly eliminated within the blood, in particular by natural killer (NK) cells [2-4].

The importance of the interaction of tumor cells with platelets for hematogenous metastasis is well recognized. Early studies have shown that tumor cells interact directly with platelets and that depletion of platelets or inhibition of their function leads to a decrease in metastasis [5-7]. Platelets may contribute to metastasis by accumulating on arrested tumor cells and thus protecting them from clearance by NK cells [3]. In addition, platelets may promote metastasis by facilitating tumor cell trapping and adhesion [8]. The interaction of tumor cells with platelets results in the expression and activation of adhesion molecules on the surface of the tumor cells; these molecules allow the tumor cells to bind to endothelial cells, emigrate, and metastasize [9].

We have previously shown that acid sphingomyelinase (Asm) plays a key role in this process: the contact of malignant mouse or human melanoma cells with platelets induces the rapid activation and release of secretory Asm from activated platelets. Secreted Asm binds to the surface of adjacent tumor cells and leads to the generation of ceramide. Ceramide molecules are very hydrophobic and spontaneously associate with each other to form small ceramide-enriched microdomains that fuse to large ceramide-enriched membrane platforms. Within these ceramide-enriched membrane domains of the tumor cells, activated β1 integrin molecules cluster and mediate the adhesion of the tumor cells to vascular structures in vivo and in vitro, thus promoting metastasis [9].

Our previous results showed that integrins regulated by ceramide play a crucial role in metastasis. This effect is mainly due to differences in the adhesive properties of the tumor cells after integrin activation [9]. However, our data do not exclude that other signaling events are elicited by ceramide or that other signaling events occur prior to or in consequence of the activation of integrins. We therefore investigated a panel of intracellular signaling events, which are known to be involved in metastasis, after stimulation of tumor cells with acid sphingomyelinase, which mimics the effects of platelet secreted Asm.

Ezrin is a cytoplasmic peripheral membrane protein and belongs to the ezrin/moesin/radixin (ERM) protein family. It serves as an intermediate between the plasma membrane and the actin cytoskeleton. It has been shown to be involved in metastasis and its function is regulated by tyrosine phosphorylation [10, 11]. Focal adhesion kinase (FAK) is involved in various signaling pathways in cancer cells that promote cancer growth and metastasis. This includes the kinase dependent control of cell motility, invasion, cell survival and transcriptional events [12]. PLCγ is activated by receptor and non-receptor tyrosine kinases. PLCγ activation leads to the formation of the second messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3), which in turn activate protein kinase C (PKC) and intracellular calcium mobilization [13]. PLCγ has been shown to be involved in cell growth, migration, and invasion [14]. Furthermore, it has been shown to be involved in the activation of integrins in leukocytes [15]. P44/42 MAPK (ERK1/2) is involved in the activation of ribosomal S6 kinases (RSK), which has been found to regulate integrin-activation and signaling [16, 17]. P38K has been shown to be involved in the trans-endothelial migration of neutrophils [18] and colon cancer cells [19]. P38K in conjunction with P13K has been shown to be involved in the activation of α5β1 integrins in colon carcinoma cells after stimulation with P-selectin [20]. Furthermore, it has been shown that p38alpha-heterozygous mice have significantly less metastasis of B16 melanoma and Lewis lung carcinoma cells into the lung in an experimental mouse model of hematogenous metastasis [21]. JNK belongs to the MAPK family
and is mainly activated during cellular stress stimuli. However, JNK is also involved in β1 integrin-mediated leukocyte migration on fibronectin [22]. However, intracellular signaling mechanisms elicited by ceramide and the involvement of such ceramide-controlled intracellular signaling pathways in tumor metastasis are unknown. Ceramide has been shown to bind to several intracellular molecules, in particular cathepsin D [23], phospholipase A2 [24], kinase suppressor of Ras [25], ceramide-activated protein serine/threonine phosphatases (CAPPs) [26], protein kinase C isoforms [27, 28], light chain IIIB (LCIIIB), and protein phosphatase 2A-inhibitor 2 [29, 30]. Thus, ceramide can directly stimulate signaling pathways that may be involved in tumor cell metastasis.

Here, we investigated whether generating ceramide within the plasma membrane generates specific signaling events in mouse and human melanoma cells and whether at least some of these events are required for tumor metastasis. To generate ceramide within the plasma membrane, we added exogenous acid sphingomyelinase, which mimics the effects of secreted Asm. We found that treating melanoma cells with exogenous Asm activates multiple intracellular signaling events, including p38 kinase (p38K). Furthermore, we show that the stimulation of p38K is necessary for the adhesion of tumor cells to lung endothelial cells and for pulmonary metastasis of tumor cells in vivo.

Materials and Methods

Mice

Asm (Smpd1)-deficient mice and syngeneic wild-type (WT) littermates were bred on a C57BL/6 (Jackson Laboratory, Bar Harbor, ME) background. Mice were bred and housed in the vivarium of the University of Duisburg-Essen, Germany, or the University of Cincinnati, USA, under specific pathogen-free conditions as recommended by the Federation of European Laboratory Animal Science Associations (FELASA; 2002). All procedures performed on mice were approved by the Animal Care and Use Committee of the Bezirksregierung Düsseldorf, Düsseldorf, Germany, or local committees. This study used female mice aged 6 to 7 weeks.

Mouse platelet isolation

Blood was obtained by tail vein puncture and was collected into a tube containing 0.38% sodium citrate (as an anticoagulant) in 9 mL phosphate-buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate dibasic, and 2 mM potassium phosphate monobasic; pH 7.2), supplemented with 3.5% fatty acid–free bovine serum albumin (BSA; Roth, Karlsruhe, Germany). After incubation for 15 min at 37°C, samples were centrifuged at 120 × g without brake for 20 min at room temperature. The supernatant was collected, and platelets were pelleted by centrifugation at 1340 × g for 10 min. Platelets were washed in Tyrode’s buffer consisting of 134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, and 1 mM MgCl2. The isolated platelets were immediately used for co-incubation experiments.

Isolation of human platelets

Human blood samples were obtained from healthy volunteers (with the permission of the Ethics Commission of the University of Duisburg-Essen; Nr. 05-2768). The blood was anti-coagulated with citrate, diluted in 45 mL PBS supplemented with 3.5% BSA, carefully mixed, and incubated for 20 min at 37°C. Leukocytes and erythrocytes were pelleted by centrifugation at 100 × g for 20 min. Next, 50 nM prostaglandin E1 (PGE1; Sigma) was added to the supernatant to prevent activation, and the samples were centrifuged at 600 × g for 10 min. Platelets were pelleted by centrifugation at 1340 × g for 10 min. Platelets were washed in Tyrode’s buffer consisting of 134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, and 1 mM MgCl2. The isolated platelets were immediately used for co-incubation experiments.

Cell culture

B16F10 melanoma cells were cultured in Gibco Minimum Essential Medium (MEM; Invitrogen, Karlsruhe, Germany) supplemented with 10 mM HEPES (pH 7.4, Carl Roth GmbH, Karlsruhe, Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 µM nonessential amino acids, 100 U/mL penicillin, 100
µg/mL streptomycin (all from Invitrogen) and 10 % fetal calf serum (PAA Laboratories GmbH, Coelbe, Germany). To prevent selection and overgrowth of specific clones, all cultures were re-established from a frozen sample after 4 weeks. Human melanoma (HM) UKRV-Mel-06a cells were grown in RPMI 1640 supplemented with 10 % fetal calf serum (FCS), L-glutamine (2 mM), and penicillin/streptomycin solution (5 U/mL; all from PAA Laboratories GmbH) and were split every 3 days to ensure consistent proliferation behavior. Cells were maintained at 37 °C and 5% CO₂.

In vivo metastasis

B16F10 melanoma cells were brought into suspension by treatment with cell dissociation solution (Gibco, Life Technologies, Paisley, UK) and washed extensively in PBS. 1 x 10⁶ B16F10 cells were injected in a volume of 200 µL into each mouse via the tail vein. In some experiments tumor cells were treated with the specific p38K inhibitor SB239063 (10 µM) for 15 min and washed as above before injection.

The number of tumor metastases in the lung was determined 14 days after injection by counting macroscopically visible metastases in serial sections 1 mm thick.

In vivo adhesion/trapping of tumor cells in the lung

B16F10 melanoma cells were labeled for 48 h with 1 µCi/mL ³H-thymidine (185 GBq/mmol; Hartmann Analytic GmbH, Braunschweig, Germany) and washed 3 times in HEPES/saline (H/S) buffer consisting of 132 mM NaCl, 20 mM HEPES (pH 7.4), 5 mM KCl, 1 mM CaCl₂, 0.7 mM MgCl₂, and 0.8 mM MgSO₄. The cells were then intravenously injected into mice, and the mice were sacrificed after 30 min. The lungs were flushed for 2 min with 0.9 % NaCl and were then removed and homogenized. The level of radioactivity in the lung was determined by liquid scintillation counting. If indicated, B16F10 cells were pretreated with the specific p38K inhibitor SB239063 (10 µM) as described above.

Stimulation, lysis, and Western blots

Melanoma cells were brought into suspension by treatment with cell dissociation solution (Gibco, Life Technologies, Paisley, UK), washed extensively, and resuspended in H/S. 1 x 10⁶ B16F10 or HM cells were then stimulated for different times with 5 U/mL acid sphingomyelinase purified from human placenta (Sigma) or co-incubated with 5 x 10⁵ wild-type or Asm-deficient platelets, respectively. B16F10 cells or platelets alone were used as controls.

Stimulation was terminated by lysis in a buffer consisting of 25 mM Tris-HCl (pH 7.4), 125 mM NaCl, 10 mM EDTA, 10 mM sodiumpyrophosphate, 3% IGEPAL, and 10 µg/mL each of aprotinin and leupeptin (TN3/AL). The solution was left on ice for 5 min, centrifuged at 18,000 x g at 4°C for 5 min for pelleting insoluble material, and added to 5 x sodium dodecyl sulphate (SDS) sample buffer. Samples were boiled, separated on 7.5% to 10% SDS-polyacrylamide gel electrophoresis (PAGE) gels, blotted onto nitrocellulose membranes, and blocked with 4 % BSA in PBS for 45 min. The blots were incubated with 1 µg/mL of one of the following primary antibodies: anti–phospho-PLCγ (phospholipase C gamma), anti–phospho-p38K, anti–phospho-Ezrin, anti–phospho-ERK (extracellular signal-related kinase), anti–phospho-JNK (c-Jun N-terminal kinase), anti–phospho-FAK (focal adhesion kinase), anti–phospho-Pi3K (phosphoinositide 3-kinase), or anti–phospho-Akt (protein kinase B; all from Cell Signaling, Danvers, Massachusetts, U.S.A). Actin blots of the following primary antibodies: anti–actin antibodies were from Santa Cruz Inc., Dallas, Texas, U.S.A.

Membranes were incubated with primary antibodies for 60 min at room temperature, washed 6-times in Tris-buffered saline (TBS) supplemented with 0.05 % Tween 20, incubated for 60 min with alkaline phosphatase (AP)-coupled secondary antibodies (all diluted 1:25,000-fold, Santa Cruz Inc.), and developed with a chemoluminescence system.

Adhesion assays

4 x 10⁵ B16F10 or HM cells were pre-incubated with 10 µM SB239063 for 15 min or incubated with DMSO in the respective concentration as control and then stimulated with 5 U/mL Asm (Sigma) for 5 min at 37°C. After the addition of 500 µL fully supplemented MEM medium, tumor cells were transferred to fibronectin-coated glass cover slips (BioPure) in 24-well plates (Falcon, BD Biosciences) for 60 s at 37°C. Unbound tumor cells were washed away with PBS (pH 7.4), and cells were fixed with 2 % buffered PFA for 15 min. After being washed with PBS for 5 min, adherent cells were analyzed with a Leica fluorescence microscope counting the number of adherent tumor cells on the coverslip (diameter 12 mm).
Analysis of active β1 integrin in human melanoma cells

Human melanoma cells were collected as described above, washed in H/S buffer and stimulated for 5 minutes with 5 U/mL purified Asm (Sigma) or left untreated. Before stimulation, cells were pre-incubated with 10 μM SB239063 to inhibit p38K or with DMSO 1:1000 as control. The stimulation was stopped by adding ice cold H/S buffer, cells were washed twice in ice cold H/S buffer, incubated for 30 min with 1 μg/mL anti-active β1 integrin antibody (clone: HUTS-4; Millipore), washed again twice in ice cold H/S buffer and stained for 30 min with FITC-coupled anti-mouse antibodies. Cells were washed, resuspended in ice cold H/S buffer and analyzed on a Becton Dickinson FACS calibur.

Statistical Analyses

Data are presented as arithmetic means ± SD. Samples were tested for normal distribution with the David-Pearson-Stephens test. Differences were examined for statistical significance with t-test or Tukey’s test, as indicated in the figure legends. All data were obtained from independent measurements.

Results

Treatment of murine or human melanoma (HM) cells with sphingomyelinase induces intracellular signaling events

First, we investigated Asm/ceramide-controlled protein tyrosine phosphorylation within melanoma cells as a first sign of activating signaling transduction. Stimulation of B16F10...
or human melanoma (HM) cells with exogenous acid sphingomyelinase resulted in tyrosine phosphorylation of several cellular proteins in B16F10 and HM cells, as evidenced by the analysis of tyrosine phosphorylation in whole-cell lysates (Fig. 1A). In addition, we observed tyrosine-phosphorylation of PLCγ (Fig. 1B) and serine/threonine phosphorylation of stress-activated protein kinases p38K (Fig. 1C), ezrin (Fig. 1D), and ERK (Fig. 1E). In contrast, we did not detect an increase of phosphorylation as an indicator of the activation of JNK (Fig. 2A), PI3K (Fig. 2B), or FAK (Fig. 2C) in melanoma cells treated with sphingomyelinase. Consistent with the lack of JNK activation in these cells, we also did not detect the phosphorylation/activation of c-Jun (Fig. 2D) after sphingomyelinase treatment. Finally, treatment with extracellular sphingomyelinase also induced a decrease in the phosphorylation of Akt (Fig. 3), a finding suggesting that this kinase is inactivated by sphingomyelinase-generated ceramide.

P38 kinase is required for B16F10 metastasis in vivo

Our former results show that acid sphingomyelinase is secreted by platelets and acts on the cell surface of tumor cells to generate ceramide [9]. Therefore, we investigated several signaling events after co-incubation of tumor cells with wild-type or Asm-deficient platelets. In accordance with our findings with B16F10 and HM cells exposed to exogenous sphingomyelinase, we also detected the activation of p38K in B16F10 melanoma cells upon co-incubation with wild-type platelets, whereas the activation of p38K was much less pronounced after the incubation of B16F10 cells with Asm-deficient platelets (Fig. 4A), a finding indicating that Asm plays an important role in the activation of p38K in melanoma cells in the co-incubated samples. We observed no differences in the phosphorylation/activation of ezrin or FAK upon incubation of B16F10 cells with wild-type or Asm-deficient platelets (Fig. 4B), a finding indicating that these signaling events, although generated by exogenous sphingomyelinase, can be also activated independently of Asm upon the contact of platelets with B16F10 cells.

To determine the role of p38K activation in tumor metastasis, we used the specific inhibitor SB239063 to inhibit the activity of this kinase in [3H]-thymidine-labeled B16F10
tumor cells. Since tumor cells rapidly adhere to the endothelial cells in the lung, we investigated tumor cell trapping 30 minutes after injection. The results show that pre-incubating the tumor cells with 10 µM SB239063 prevents adhesion and trapping of the tumor cells in the lung in vivo (Fig. 5).

Furthermore, we injected mice with B16F10 cells that had been pre-incubated with 10 µM SB239063 for 15 min and determined tumor metastasis to the lungs in vivo after 14 days, when adherent tumor cells formed metastases that were macroscopically visible. Inhibition
Inhibition of p38K activity in B16F10 melanoma led to a significant decrease in the number of tumor metastasis in vivo (Fig. 6).

**P38 kinase is responsible for tumor cell adhesion via β1 integrin activation**

To gain insights into the mechanism of p38K mediated metastasis of B16F10 melanoma cells, we determined whether p38K regulates Asm derived cell adhesion. Therefore, we stimulated B16F10 and human melanoma cells with Asm in presence or absence of SB239063 and determined adhesion of tumor cells on fibronectin covered glass cover slips. We found that, in accordance to our previous data [9], Asm promotes adhesion of B16F10 melanoma and HM cells on fibronectin covered glass cover slips. This effect was completely prevented by inhibition of p38K with SB239063 (Fig. 7A + B) indicating that p38K functions upstream of β1 integrin. Furthermore, SB239063 inhibited the activation of β1 integrin in human
Fig. 7. Stimulation of tumor cells with Asm promotes the adhesion to fibronectin coated glass cover slips and the activation of β1 integrins on the cell surface, both effects are abolished by p38K inhibition. 4 x 10^5 B16F10 melanoma cells (A) or HM cells (B) were stimulated for 5 minutes with 5 U/mL Asm or with H/S buffer as control, SB239063 was added when indicated. Tumor cells were then incubated for 60 seconds on fibronectin coated cover slips, washed extensively, fixed, and adhesion of tumor cells was determined. The graphs display the mean ± SD of tumor cells adhering to fibronectin coated cover slips from one representative of at least 4 independent experiments. Each experiment was performed in triplicates. Statistical significance was determined by analysis of variance (ANOVA), *** p < 0.001. For pairwise comparisons, p-values were determined using the Tukey’s test, *** p < 0.001. (C) HM cells were stimulated for 5 minutes with 5 U/mL Asm or with H/S buffer as control (untreated). 10 µM SB239063 was added when indicated. Activation of β1 integrin was measured by cytomtrical analysis upon staining with FITC-labeled HUTS-4 antibodies. Shown is one representative of 4 experiments in total.

Discussion

In the present study we investigated signaling events induced in murine and human melanoma cells by exogenous sphingomyelinasese. We have previously shown that the interaction of melanoma cells with platelets results in the release of Asm from platelets and that the secreted Asm acts on the surface of the tumor cells to generate ceramide. Ceramide forms ceramide-enriched membrane platforms that serve to cluster and activate integrin molecules in the malignant melanoma cells. The clustering and activation of integrins in ceramide-enriched domains were shown to be necessary for adhesion of the tumor cells to endothelial cells in vitro and in vivo [9]. However, although the results of these studies demonstrated that integrins, regulated by ceramide, play a crucial role in tumor cell metastasis, they certainly do not exclude the possibility that other signaling events are elicited by ceramide and contribute to melanoma metastasis. The studies also did not define any intermediates between ceramide and integrins. In the study reported here, we investigated such signaling events and found that exogenous acid sphingomyelinasese induces activation-associated phosphorylation of PLCγ, p38K, ezrin, and ERK, whereas Asm does not affect the phosphorylation/activation of JNK, c-Jun, PI3K, and FAK; in fact, it even decreases the phosphorylation and, thereby, the activity of Akt in melanoma cells. The importance of Asm in the activation of p38K was shown by the co-incubation of wild-type and Asm-deficient platelets with melanoma cells. These experiments demonstrated that...
p38K activation within tumor cells strictly depends on Asm expression in platelets. In contrast, the phosphorylation of ezrin and FAK also occurred after the co-incubation of B16F10 melanoma cells with Asm-deficient platelets, a finding indicating that phosphorylation of these proteins can be triggered not only by pathways induced by exogenous sphingomyelinase, but also by pathways independent of this enzyme when platelets contact tumor cells. In particular, our data indicate phosphorylation of ezrin in tumor cells after the addition of exogenous Asm, but also upon contact with Asm-deficient platelets. This discrepancy can be explained by the following scenario: While exogenous Asm induces S1P formation in tumor cells [31], the physiological contact of wild-type or Asm-deficient platelets with tumor cells leads to the release of S1P that is stored within platelets [32]. S1P then induces the phosphorylation of ezrin [31]. Thus, ezrin-phosphorylation depends on S1P, which can be either secreted from platelets independent of the Asm or formed from ceramide after pharmacological treatment of the tumor cells with Asm.

We further investigated the significance of the Asm-induced activation of p38K in vivo and in vitro. Therefore, we inhibited the activity of p38K with SB239063, which is a reversible inhibitor of p38K. It has been shown that the IC50 of SB239063 to inhibit p38K is 44nM. Furthermore, even at the dosage of 10 µM, which we used, no significant inhibition of other tyrosine kinases was detected [33]. We found that pharmacological inhibition of the activity of p38K prevents early adhesion of B16F10 melanoma cells to endothelial cells in vivo and tumor metastasis, as determined by measurements of macroscopically visible metastases 14 days after the intravenous injection of tumor cells. Although the final read-out is metastatic growth in the lung after 14 days, this long-term outcome is determined by the platelet-tumor cell interaction and the subsequent tumor cell activation/adhesion to endothelial cells occurring within seconds to minutes after platelet-tumor cell contact. The tumor cells that do not adhere are degraded in the host, most likely by natural killer cells [2-4]. Furthermore, we performed in vitro adhesion assays. We show that incubation of tumor cells with Asm increases the adhesiveness of tumor cells on fibrinogen coated glass cover slip, an effect that is nearly completely reverted by the pharmacological inhibition of p38K. Additionally, we measured activation of β1 integrin on melanoma cells using the HUTS-4 antibody, which specifically detects activated β1 integrin. Co-incubation of tumor cells with Asm leads to an activation of β1 integrin on the cell surface, an effect which is again completely reverted by the pharmacological inhibition of p38K.

Our data indicate a signaling cascade from the Asm via p38K to the activation of β1 integrin on the cell surface finally executing tumor cell adhesion. Since the latter is the prerequisite for the formation of metastasis in the lung, these findings clearly demonstrate the importance of p38K activation for tumor metastasis in vivo.

At present, the exact function of p38K in the process of tumor cell adhesion and metastasis is unknown. Our data suggest that p38K is involved in the inside-out signaling of β1 integrins and, thus, is involved in the activation of integrins, which then mediate tumor cell adhesion. On the other hand, p38K may be still part of the machinery activated by integrins after they cluster in ceramide-enriched domains. p38K may transfer the signal from integrins to the cytoskeleton, in particular the actin cytoskeleton, which has previously been shown to be regulated by p38K [34, 35]. Furthermore, p38K might be regulated by as yet unknown signaling events that are independent of integrins and that link ceramide and ceramide-enriched membrane domains to p38K, which may be required for tumor cell metastasis, for instance by regulation of the cytoskeleton.

In addition to the regulation of elements in the cytoskeleton, p38K may also be involved in gene regulation, as previously shown for the upregulation in expression of some molecules and receptors that mediate tumor cell invasion, in particular urokinase plasminogen activator/urokinase-specific surface receptor and metalloproteases [36, 37]. However, because p38K inhibitors immediately prevented the adhesion of B16F10 cells, a mechanism involving transcription and/or translation seems unlikely.

P38K may also be involved in the rapid upregulation of the expression of adhesion receptors, such as intercellular adhesion molecule 1 (ICAM-1), upon the activation of ma-
lignant tumor cells, perhaps by mobilizing intracellular storage vesicles that contain these receptors [38].

Finally, it may be possible that the activation of p38K is involved in the formation and the release of cytokines, such as IL-1 or TNF-α, that act locally on the endothelial cells in the lungs to change the expression of adhesion molecules in the luminal layer of the plasma membrane to allow the tumor cells to adhere to endothelial cells and metastasize [39].

A previous study found that p38K expression in platelets and endothelial cells is important for tumor cell metastasis [21], whereas our study focused on the role of p38K expression in the malignant tumor cells. Therefore, p38K may be involved in different pathways that mediate tumor cell metastasis in benign host cells and malignant tumor cells.

It seems very unlikely that ceramide directly regulates any of the signaling molecules that were identified in the present study. Ceramide generated by extracellular sphingomyelinase localizes into the outer leaflet of the plasma membrane, whereas the identified signaling molecules are cytoplasmic proteins. It seems much more likely that the effects of ceramide are mediated by ceramide-enriched membrane domains that form after the generation and clustering of ceramide, and may serve to trap receptors and signaling molecules that then transfer the signal into the cell. The ability of ceramide-enriched membrane domains to cluster proteins is very likely to be mediated by their biophysical properties. Thus, ceramide-enriched membrane domains are tightly packed, and stable ceramide-enriched membrane domains are highly hydrophobic and may even exist in a liquid ordered state, which may facilitate the trapping of specific proteins in these domains. Our studies have shown that ceramide-enriched membrane platforms trap and cluster receptor molecules, a process resulting in as much as a 100-fold amplification of signal transduction of the cognate receptor. The formation of ceramide-enriched membrane domains is triggered by many diverse receptors and stimuli, including CD95 [40, 41], CD40 [42], DR5 [43], FcγRII [44], PAF receptor [45], CD14 [46], nicotinamide adenine dinucleotide phosphate (NADPH) oxidases [47]; infection with P. aeruginosa [48], S. aureus [49], N. gonorrhoeae [50], measles virus [51], or Rhinovirus [52]; and the application of γ irradiation [53, 54], UV light [55], Cu²⁺ [56], cisplatin [57], or gemcitabine [58]. The reorganization properties of these platforms can be used for signaling. Because p38K is activated by reactive oxygen species (ROS) [59], the clustering of NADPH oxidases in ceramide-enriched membrane domains of melanoma cells after exposure to extracellular sphingomyelinase or upon incubation with wild-type platelets may result in the increased production and release of ROS. These ROS may then trigger the activation of p38K and thereby reorganize the cytoskeleton of the tumor cells to allow adhesion and metastasis.

At present, the molecular mechanisms that mediate receptor clustering are largely unknown. In previous studies we used chimeric constructs of CD40 and CD45 because of the observation that CD40 clusters in ceramide-enriched membrane domains whereas CD45 does not [60]. The results of these studies showed that the transmembranous domain of CD40 determines receptor clustering [60]. However, the molecular details of that process have not yet been defined.

In summary, we found that stimulating mouse and human melanoma cells with extracellular sphingomyelinase or with wild-type platelets that release Asm results in the activation of p38K within the tumor cells, whereas co-incubating the tumor cells with Asm-deficient platelets fails to activate p38K. Inhibition of p38K activity prevents tumor cell trapping and metastasis in the lung in vivo, a finding suggesting the importance of p38K activation via sphingomyelinase induced ceramide accumulation for tumor metastasis. Since inhibiting the activity of the kinase acutely reduces tumor metastasis, this kinase may also serve as a novel pharmacological target for preventing the immediate spread of tumor cells, for instance during manipulation of a tumor during a surgical procedure. P38K inhibitors were used in clinical trials for other indications, like for example chronic obstructive lung disease and rheumatoid arthritis, and have been show to be well tolerable [61, 62]. Thus, inhibition of p38K might be a novel approach to prevent tumor metastasis.
Acknowledgments

We thank F. Witte and S. Harde for excellent help with the manuscript and with animal experiments. This study was supported by DFG grant Gu 335/24-1 to EG.

Disclosure Statement

The authors have nothing to disclose.

References


